Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

4,848 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Multicenter, prospective, observational study of chemotherapy-induced dysgeusia in gastrointestinal cancer.
Ito K, Yuki S, Nakatsumi H, Kawamoto Y, Harada K, Nakano S, Saito R, Ando T, Sawada K, Yagisawa M, Ishiguro A, Dazai M, Iwanaga I, Hatanaka K, Sato A, Matsumoto R, Shindo Y, Tateyama M, Muranaka T, Katagiri M, Yokota I, Sakata Y, Sakamoto N, Komatsu Y. Ito K, et al. Among authors: harada k. Support Care Cancer. 2022 Jun;30(6):5351-5359. doi: 10.1007/s00520-022-06936-4. Epub 2022 Mar 15. Support Care Cancer. 2022. PMID: 35292848 Free PMC article.
Efficacy and Safety of Bolus 5-Fluorouracil and L-Leucovorin as Salvage Chemotherapy for Oral Fluoropyrimidine-Resistant Unresectable or Recurrent Gastric Cancer: A Single Center Experience.
Muranaka T, Yuki S, Komatsu Y, Sawada K, Harada K, Kawamoto Y, Nakatsumi H, Sakamoto N. Muranaka T, et al. Among authors: harada k. J Gastric Cancer. 2016 Sep;16(3):177-181. doi: 10.5230/jgc.2016.16.3.177. Epub 2016 Sep 30. J Gastric Cancer. 2016. PMID: 27752395 Free PMC article.
Study protocol of HGCSG1404 SNOW study: a phase I/II trial of combined chemotherapy of S-1, nab-paclitaxel and oxaliplatin administered biweekly to patients with advanced gastric cancer.
Kawamoto Y, Komatsu Y, Yuki S, Sawada K, Muranaka T, Harada K, Nakatsumi H, Fukushima H, Ishiguro A, Dazai M, Hatanaka K, Nakamura M, Iwanaga I, Uebayashi M, Sogabe S, Kobayashi Y, Miyagishima T, Ono K, Sakamoto N, Sakata Y. Kawamoto Y, et al. Among authors: harada k. BMC Cancer. 2017 Dec 8;17(1):837. doi: 10.1186/s12885-017-3850-z. BMC Cancer. 2017. PMID: 29221445 Free PMC article. Clinical Trial.
Impact of single-heterozygous UGT1A1 on the clinical outcomes of irinotecan monotherapy after fluoropyrimidine and platinum-based combination therapy for gastric cancer: a multicenter retrospective study.
Nakano S, Yuki S, Kawamoto Y, Nakatsumi H, Ando T, Kajiura S, Yoshikawa A, Harada K, Hatanaka K, Tanimoto A, Ishiguro A, Honda T, Dazai M, Sasaki T, Sakamoto N, Komatsu Y. Nakano S, et al. Among authors: harada k. Int J Clin Oncol. 2020 Oct;25(10):1800-1806. doi: 10.1007/s10147-020-01720-y. Epub 2020 Jul 14. Int J Clin Oncol. 2020. PMID: 32666389 Free PMC article.
A Phase I Trial of Oxaliplatin, Irinotecan, and S-1 Combination Therapy (OX-IRIS) as Chemotherapy for Unresectable Pancreatic Cancer (HGCSG 1403).
Kawamoto Y, Nakatsumi H, Harada K, Muranaka T, Ishiguro A, Kobayashi Y, Hayashi H, Yuki S, Sawada K, Yagisawa M, Nakano S, Sakamoto N, Komatsu Y. Kawamoto Y, et al. Among authors: harada k. Oncologist. 2021 Oct;26(10):e1675-e1682. doi: 10.1002/onco.13838. Epub 2021 Jun 21. Oncologist. 2021. PMID: 34050586 Free PMC article. Clinical Trial.
Phase II Study of Continued Trastuzumab Plus Irinotecan in Patients with HER2-positive Gastric Cancer Previously Treated with Trastuzumab (HGCSG 1201).
Kawamoto Y, Yuki S, Meguro T, Hatanaka K, Uebayashi M, Nakamura M, Okuda H, Iwanaga I, Kato T, Nakano S, Sato A, Harada K, Oba K, Sakata Y, Sakamoto N, Komatsu Y. Kawamoto Y, et al. Among authors: harada k. Oncologist. 2022 May 6;27(5):340-e374. doi: 10.1093/oncolo/oyab062. Oncologist. 2022. PMID: 35303078 Free PMC article. Clinical Trial.
Study protocol of the HGCSG1803: a phase II multicentre, non-randomised, single-arm, prospective trial of combination chemotherapy with oxaliplatin, irinotecan and S-1 (OX-IRIS) as first-line treatment for metastatic or relapsed pancreatic cancer.
Nakano S, Kawamoto Y, Yuki S, Harada K, Miyagishima T, Sogabe S, Dazai M, Sato A, Ishiguro A, Nakamura M, Kajiura S, Takahashi Y, Tateyama M, Hatanaka K, Tsuji Y, Sasaki T, Shindo Y, Kobayashi T, Yokota I, Sakamoto N, Sakata Y, Komatsu Y. Nakano S, et al. Among authors: harada k. BMJ Open. 2022 May 9;12(5):e048833. doi: 10.1136/bmjopen-2021-048833. BMJ Open. 2022. PMID: 35534074 Free PMC article.
4,848 results